RA
Rosalind Advisors Portfolio holdings
AUM
$283M
1-Year Est. Return
91.7%
1 Year Est. Return
+91.7%
AUM
$283M
AUM Growth
+$76.3M
(+37%)
Holding
42
Top Buys
| 1 | +$9.26M | |
| 2 | +$7.95M | |
| 3 | +$7.56M | |
| 4 |
uniQure
QURE
|
+$7.3M |
| 5 |
MediWound
MDWD
|
+$6.16M |
Top Sells
| 1 | +$9.57M | |
| 2 | +$8.36M | |
| 3 | +$7.43M | |
| 4 |
IDEAYA Biosciences
IDYA
|
+$4.38M |
| 5 |
Pharvaris
PHVS
|
+$3.94M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Biofrontera
BFRI
$9.52M
| $1.12M | 0.38% |
1,140,764
+164,316
|
|
||
27
Astria Therapeutics
ATXS
$722M
| $1.11M | 0.38% |
+1,542,520
|
|
||
28
Trevi Therapeutics
TRVI
$1.69B
| $915K | 0.31% |
100,000
-200,000
|
|
||
29
Kura Oncology
KURA
$1.06B
| $885K | 0.3% |
100,000
|
|
||
30
Replimune Group
REPL
$784M
| – | – |
-900,000
|
|
||
|
CMPS
31
Compass Pathways
CMPS
$533M
| – | – |
-482,651
|
|
||
32
Crinetics Pharmaceuticals
CRNX
$4.32B
| – | – |
0
|
|
||
33
INmune Bio
INMB
$46.3M
| – | – |
0
|
|
||
34
KalVista Pharmaceuticals
KALV
$731M
| – | – |
-157,725
|
|
||
35
iShares S&P 100 ETF
OEF
$29B
| – | – |
0
|
|
||
36
Ovid Therapeutics
OVID
$127M
| – | – |
-500,000
|
|
||
|
37
Pharvaris
PHVS
$1.84B
| – | – |
-223,627
|
|
||
38
Invesco QQQ Trust
QQQ
$405B
| – | – |
0
|
|
||
39
SPDR S&P 500 ETF Trust
SPY
$700B
| – | – |
0
|
|
||
40
Scholar Rock
SRRK
$4.49B
| – | – |
0
|
|
||
41
UroGen Pharma
URGN
$1.35B
| – | – |
-542,366
|
|
||
42
State Street SPDR NYSE Technology ETF
XNTK
$1.46B
| – | – |
0
|
|